Table 1
| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S1207-Brst,Adj,Endocrine+/-Everolimus | 01-MAY-19 | N | ALLIANCE | 276 | |
| ECOG-ACRIN | 253 | |||||
| NRG | 414 | |||||
| SWOG | 996 | |||||
| sum | 1939 | |||||
| S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 | 15-JUN-19 | N | ALLIANCE | 62 | ||
| ECOG-ACRIN | 36 | |||||
| NRG | 66 | |||||
| SWOG | 180 | |||||
| sum | 344 | |||||
| S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | Y | ALLIANCE | 62 | |||
| ECOG-ACRIN | 67 | |||||
| NRG | 151 | |||||
| SWOG | 306 | |||||
| sum | 586 | |||||
| S1706-Breast, Inflammatory, RT +/- Olaparib | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 8 | |||||
| SWOG | 7 | |||||
| sum | 21 | |||||
| CCD | S1415CD-TrACER CSF Standing Order Intervention for FN | Y | ECOG-ACRIN | 374 | ||
| SWOG | 2645 | |||||
| S1415CD | Y | ALLIANCE | 332 | |||
| NRG | 165 | |||||
| sum | 3516 | |||||
| S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 1 | |||||
| SWOG | 35 | |||||
| sum | 41 | |||||
| ERLYTX | S1609-Rare Tumor, Comb Nivo/Ipi | Y | ALLIANCE | 92 | ||
| ECOG-ACRIN | 70 | |||||
| NRG | 111 | |||||
| SWOG | 407 | |||||
| sum | 680 | |||||
| GI | S1613-mCRC, Adv/Met, TP vs CETIRI | Y | ALLIANCE | 3 | ||
| ECOG-ACRIN | 2 | |||||
| SWOG | 18 | |||||
| sum | 23 | |||||
| S1815-Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | Y | ALLIANCE | 33 | |||
| ECOG-ACRIN | 28 | |||||
| NRG | 10 | |||||
| SWOG | 48 | |||||
| sum | 119 | |||||
| GU | S1500-pRCC,Adv, Sunitinib vs MET inhib | Y | ALLIANCE | 24 | ||
| CCTG | 23 | |||||
| ECOG-ACRIN | 17 | |||||
| NRG | 11 | |||||
| SWOG | 68 | |||||
| sum | 143 | |||||
| S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 28-AUG-19 | T | ALLIANCE | 68 | ||
| ECOG-ACRIN | 40 | |||||
| NRG | 41 | |||||
| SWOG | 354 | |||||
| sum | 503 | |||||
| S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab | 05-JUL-19 | N | ALLIANCE | 41 | ||
| CCTG | 9 | |||||
| ECOG-ACRIN | 27 | |||||
| NRG | 20 | |||||
| SWOG | 75 | |||||
| sum | 172 | |||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | Y | ALLIANCE | 19 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 8 | |||||
| SWOG | 89 | |||||
| sum | 119 | |||||
| S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 1 | |||||
| SWOG | 9 | |||||
| sum | 11 | |||||
| LEUK | S1318-ALL, Age 65+, Ph±, Blinatumomab | Y | ALLIANCE | 15 | ||
| ECOG-ACRIN | 6 | |||||
| SWOG | 27 | |||||
| sum | 48 | |||||
| S1712-CML, Chronic Phase, TKI +/- Ruxolitinib | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 1 | |||||
| SWOG | 10 | |||||
| sum | 13 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 134 | ||
| ECOG-ACRIN | 76 | |||||
| NRG | 57 | |||||
| SWOG | 382 | |||||
| sum | 649 | |||||
| S1400F-Non-Match: MEDI4736 + Tremelimumab | 15-MAY-19 | T | ALLIANCE | 11 | ||
| ECOG-ACRIN | 6 | |||||
| NRG | 7 | |||||
| SWOG | 40 | |||||
| sum | 64 | |||||
| S1619-Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC | Y | ECOG-ACRIN | 1 | |||
| S1619 | Y | ALLIANCE | 1 | |||
| SWOG | 20 | |||||
| sum | 22 | |||||
| S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | Y | SWOG | 2 | |||
| sum | 2 | |||||
| S1800A-Non-Match: Ramu + Pembro vs SoC | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 1 | |||||
| SWOG | 27 | |||||
| sum | 33 | |||||
| S1900A-LOH and/or BRCA: Rucaparib | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 2 | |||||
| SWOG | 21 | |||||
| sum | 25 | |||||
| LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 15-OCT-19 | T | ALLIANCE | 6 | |
| ECOG-ACRIN | 4 | |||||
| NRG | 6 | |||||
| SWOG | 21 | |||||
| sum | 37 | |||||
| S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | Y | COG | 3 | |||
| SWOG | 9 | |||||
| sum | 12 | |||||
| MELAN | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | Y | SWOG | 31 | ||
| sum | 31 | |||||
| S1607-MELAN, Adv, T-VEC, MK-3475 | Y | ECOG-ACRIN | 5 | |||
| NRG | 1 | |||||
| SWOG | 17 | |||||
| sum | 23 | |||||
| S1616-MELAN, Adv, Ipilimumab ± Nivolumab | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 11 | |||||
| SWOG | 44 | |||||
| sum | 67 | |||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | Y | ALLIANCE | 6 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 4 | |||||
| SWOG | 41 | |||||
| sum | 56 | |||||
| MMYEL | S1702-AL Amyloidosis, Relapsed, Isatuximab | Y | ALLIANCE | 3 | ||
| ECOG-ACRIN | 14 | |||||
| NRG | 2 | |||||
| SWOG | 24 | |||||
| sum | 43 | |||||
| S1803-MM, Maintenance, Len vs Len/Dara | Y | NRG | 1 | |||
| SWOG | 12 | |||||
| sum | 13 | |||||
| PREV | S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | Y | ALLIANCE | 26 | ||
| ECOG-ACRIN | 18 | |||||
| NRG | 30 | |||||
| SWOG | 183 | |||||
| sum | 257 | |||||
| SURV | S1316-Compar. Effectiv. Trial for MBO | Y | ECOG-ACRIN | 2 | ||
| NRG | 61 | |||||
| SWOG | 121 | |||||
| S1316 | Y | ALLIANCE | 26 | |||
| sum | 210 | |||||
| S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 20 | |||
| SWOG | 104 | |||||
| S1501 | Y | ALLIANCE | 13 | |||
| NRG | 12 | |||||
| sum | 149 | |||||
| SXQOL | S1600-Bladder,Radical Cystectomy Outcomes Nutrition | 05-OCT-19 | T | ALLIANCE | 1 | |
| NRG | 1 | |||||
| SWOG | 13 | |||||
| sum | 15 | |||||